Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies

J Ying; Z Gao; H Li; G Srivastava; Paul Murray; HK Goh; CY Lim; Y Wang; T Marafioti; DY Mason; RF Ambinder; ATC Chan; Q Tao

doi:10.1111/j.1365-2141.2007.06512.x

Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies

J Ying, Z Gao, H Li, G Srivastava, Paul Murray, HK Goh, CY Lim, Y Wang, T Marafioti, DY Mason, RF Ambinder, ATC Chan, Q Tao

Cancer and Genomic Sciences

Research output: Contribution to journal › Article

48 Citations (Scopus)

Abstract

Epigenetic silencing of tumour suppressor genes (TSG) inactivates TSG functions. Previously, we identified PCDH10 as a methylated TSG in carcinomas. Here, we detected its frequent silencing and methylation in lymphoma cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell lymphoma and 1/3 of leukaemia cell lines, and in primary tumours but not in normal peripheral blood mononuclear cells or lymph nodes. PCDH10 silencing could be reversed by demethylation with 5-aza-2'-deoxycytidine. Methylation was further detected in 14% of Hodgkin lymphoma sera. Thus, PCDH10 methylation is frequently involved in lymphomagenesis and could serve as a tumour-specific biomarker.

Original language	English
Pages (from-to)	829-832
Number of pages	4
Journal	British Journal of Haematology
Volume	136
Issue number	6
DOIs	https://doi.org/10.1111/j.1365-2141.2007.06512.x
Publication status	Published - 1 Mar 2007

Keywords

methylation
tumour suppressor gene
biomarker
PCDH10
lymphoma

Access to Document

10.1111/j.1365-2141.2007.06512.x

Cite this

@article{bbf366ba54dd484da3122a5a912b645d,

title = "Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies",

abstract = "Epigenetic silencing of tumour suppressor genes (TSG) inactivates TSG functions. Previously, we identified PCDH10 as a methylated TSG in carcinomas. Here, we detected its frequent silencing and methylation in lymphoma cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell lymphoma and 1/3 of leukaemia cell lines, and in primary tumours but not in normal peripheral blood mononuclear cells or lymph nodes. PCDH10 silencing could be reversed by demethylation with 5-aza-2'-deoxycytidine. Methylation was further detected in 14% of Hodgkin lymphoma sera. Thus, PCDH10 methylation is frequently involved in lymphomagenesis and could serve as a tumour-specific biomarker.",

keywords = "methylation, tumour suppressor gene, biomarker, PCDH10, lymphoma",

author = "J Ying and Z Gao and H Li and G Srivastava and Paul Murray and HK Goh and CY Lim and Y Wang and T Marafioti and DY Mason and RF Ambinder and ATC Chan and Q Tao",

year = "2007",

month = mar,

day = "1",

doi = "10.1111/j.1365-2141.2007.06512.x",

language = "English",

volume = "136",

pages = "829--832",

journal = "British Journal of Haematology",

issn = "1365-2141",

publisher = "Wiley",

number = "6",

}

TY - JOUR

T1 - Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies

AU - Ying, J

AU - Gao, Z

AU - Li, H

AU - Srivastava, G

AU - Murray, Paul

AU - Goh, HK

AU - Lim, CY

AU - Wang, Y

AU - Marafioti, T

AU - Mason, DY

AU - Ambinder, RF

AU - Chan, ATC

AU - Tao, Q

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Epigenetic silencing of tumour suppressor genes (TSG) inactivates TSG functions. Previously, we identified PCDH10 as a methylated TSG in carcinomas. Here, we detected its frequent silencing and methylation in lymphoma cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell lymphoma and 1/3 of leukaemia cell lines, and in primary tumours but not in normal peripheral blood mononuclear cells or lymph nodes. PCDH10 silencing could be reversed by demethylation with 5-aza-2'-deoxycytidine. Methylation was further detected in 14% of Hodgkin lymphoma sera. Thus, PCDH10 methylation is frequently involved in lymphomagenesis and could serve as a tumour-specific biomarker.

AB - Epigenetic silencing of tumour suppressor genes (TSG) inactivates TSG functions. Previously, we identified PCDH10 as a methylated TSG in carcinomas. Here, we detected its frequent silencing and methylation in lymphoma cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell lymphoma and 1/3 of leukaemia cell lines, and in primary tumours but not in normal peripheral blood mononuclear cells or lymph nodes. PCDH10 silencing could be reversed by demethylation with 5-aza-2'-deoxycytidine. Methylation was further detected in 14% of Hodgkin lymphoma sera. Thus, PCDH10 methylation is frequently involved in lymphomagenesis and could serve as a tumour-specific biomarker.

KW - methylation

KW - tumour suppressor gene

KW - biomarker

KW - PCDH10

KW - lymphoma

U2 - 10.1111/j.1365-2141.2007.06512.x

DO - 10.1111/j.1365-2141.2007.06512.x

M3 - Article

C2 - 17341268

SN - 1365-2141

VL - 136

SP - 829

EP - 832

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies

Abstract

Keywords

Access to Document

Fingerprint

Cite this